To access the Libraries please log in:

Angiotensin II

Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients.
Benicar reduces serum angiotensin II, that is significantly inflammatory in numerous disease states. 


Olmesartan, an angiotensin II receptor blocker, restores cerebral hypoperfusion in elderly patients with hypertension.

A sartan derivative with a very low angiotensin II receptor affinity ameliorates
ischemic cerebral damage.

Trophic effect of olmesartan, a novel AT1R antagonist, on spinal motor neurons in vitro and in vivo.


Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor 

Beneficial effects of olmesartan, a novel angiotensin II receptor type 1 antagonist, upon acute autoimmune myocarditis 

Olmesartan Improves Coronary Flow Reserve of Hypertensive Patients Using Coronary Magnetic Resonance Imaging Compared with Amlodipine.

Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor.

Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil (atherosclerosis) 

New Data Show Olmesartan, an Angiotensin Receptor Blocker (ARB) Has Significant Anti-Atherosclerotic and Vascular Protective Effects

Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil

Olmesartan, a novel AT1 antagonist, suppresses cytotoxic myocardial injury in autoimmune heart failure  

Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial.

FDA Approves Olmesartan for the Treatment of Pediatric Hypertension 

Clinical and pharmacotherapeutic relevance of the double-chain domain of the angiotensin II type 1 receptor blocker olmesartan.

A Double-Blind, Dose-Response Study of the Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescents with Hypertension.

Olmesartan, a novel angiotensin II type 1 receptor antagonist, reduces severity of atherosclerosis in apolipoprotein E deficient mice associated with reducing superoxide production.

An evaluation of the efficacy of olmesartan medoxomil in Black patients with hypertension.

Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension.

Cross talk of tumor necrosis factor-alpha and the renin-angiotensin system in tumor necrosis factor-alpha-induced plasminogen activator inhibitor-1 production from hepatocytes.

Olmesartan improves left ventricular function in pressure-overload hypertrophied rat heart by blocking angiotensin II receptor with synergic effects of upregulation of angiotensin converting enzyme 2.

Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats.

Effects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patients. 

Olmesartan Inhibits Angiotensin II–Induced Migration of Vascular Smooth Muscle Cells Through Src and Mitogen-Activated Protein Kinase Pathways 

Beating the clock: reducing cardiovascular risk by rapid blood pressure reduction with olmesartan.

Impact of Olmesartan on Progression of Coronary Atherosclerosis

Olmesartan Reduces Atheroma  

Cardioprotective effects of angiotensin II type 1 receptor blockade with olmesartan on reperfusion injury in a rat myocardial ischemia-reperfusion model.

Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study.

Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension.

Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension.

Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil.

Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence.


The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice.


Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension.
"Improvement of glycemic control and insulin resistance was only observed in olmesartan group. ...these effects of olmesartan might be mediated by an anti-inflammatory action."

Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice.

Effects of Olmesartan, an Angiotensin II Receptor Blocker, and Amlodipine, a Calcium Channel Blocker, on Cardio-Ankle Vascular Index (CAVI) in Type 2 Diabetic Patients with Hypertension.

Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension.

Olmesartan Delays Occurrence of Microalbuminuria in Type 2 Diabetes: Presented at Renal Week 2009

Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats


Olmesartan Attenuates the Impairment of Endothelial Cells Induced by Oxidized Low Density Lipoprotein through Downregulating Expression of LOX-1


Anti-inflammatory and anti-oxidant activities of olmesartan medoxomil ameliorate experimental colitis in rats. (new)

Antiinflammatory Effects of Angiotensin II Subtype 1 Receptor Blockade in Hypertensive Patients With Microinflammation
"Olmesartan treatment ... significantly reduced serum levels of inflammatory markers; high-sensitivity C-reactive protein, high-sensitivity tumor necrosis factor-alpha, interleukin-6, and monocyte chemotactic protein-1 after 6 weeks of therapy...."


Synthesis of osteopontin (OPN) is stimulated by calcitriol (1,25-dihydroxy-vitamin D3). Stimulation of OPN expression also occurs upon exposure of cells to pro-inflammatory cytokines. The fact that OPN interacts with multiple cell surface receptors which are ubiquitously expressed makes it an active player in many physiological and pathological processes including, bone turnover, tumorigenesis, inflammation, ischemia and immune responses. This study concluded that olmesartan significantly decreases elevated osteopontin.
Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension--results from the EUTOPIA trial.


See ARBs- Studies Demonstrating Effect on Chronic Kidney Disease


"...the medoxomil-ester prodrug is rapidly and completely converted to its pharmacologically active form in the gastrointestinal mucosa, portal blood, and liver before it comes into systemic circulation."
Human Carboxymethylenebutenolidase (CMBL) as a Bioactivating Hydrolase of Olmesartan Medoxomil in Liver and Intestine 

Pharmacokinetics of CS-866 (olmesartan), a new angiotensin II receptor blocker, in healthy subjects.

Clinical efficacy and tolerability of olmesartan

Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist.

The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview.

The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction.


Targeting the angiotensin pathway in idiopathic pulmonary fibrosis.


The angiotensin II type 1 receptor antagonist olmesartan preserves cerebral blood flow and cerebrovascular reserve capacity, and accelerates rehabilitative outcomes in hypertensive patients with a history of stroke.